gptkbp:instanceOf
|
vaccine
|
gptkbp:administeredBy
|
over 100 countries
|
gptkbp:age
|
18 years and older
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
February 27, 2021
|
gptkbp:ATCCode
|
gptkb:J07BX03
|
gptkbp:boosterInterval
|
at least 2 months after primary dose
|
gptkbp:boosterRecommended
|
yes
|
gptkbp:brand
|
gptkb:Jcovden
gptkb:Johnson_&_Johnson_COVID-19_Vaccine
|
gptkbp:clinicalTrialPhase
|
gptkb:ENSEMBLE_trial
|
gptkbp:contains
|
DNA encoding SARS-CoV-2 spike protein
recombinant, replication-incompetent adenovirus
|
gptkbp:countryOfOrigin
|
gptkb:Netherlands
gptkb:United_States
|
gptkbp:developedBy
|
gptkb:Johnson_&_Johnson
gptkb:Janssen_Pharmaceuticals
|
gptkbp:doseRegimen
|
single dose
|
gptkbp:effect
|
66% against moderate to severe COVID-19 (global)
85% against severe COVID-19
|
gptkbp:emergencyServices
|
February 2021
|
https://www.w3.org/2000/01/rdf-schema#label
|
Janssen COVID-19 Vaccine
|
gptkbp:includedIn
|
gptkb:COVAX_program
|
gptkbp:indication
|
prevention of COVID-19
|
gptkbp:legalStatus
|
approved in EU
approved in WHO EUL
withdrawn in US
|
gptkbp:notRecommendedFor
|
children under 18
people with history of thrombosis with thrombocytopenia after previous dose
|
gptkbp:rareAdverseEvent
|
gptkb:Guillain-Barré_syndrome
thrombosis with thrombocytopenia syndrome
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
pain at injection site
|
gptkbp:storage
|
2–8°C
|
gptkbp:storageDuration
|
up to 3 months at 2–8°C
|
gptkbp:target
|
gptkb:COVID-19
|
gptkbp:technology
|
non-replicating viral vector
|
gptkbp:type
|
viral vector vaccine
|
gptkbp:vectorFor
|
gptkb:adenovirus_serotype_26_(Ad26)
|
gptkbp:WHOEmergencyUseListing
|
March 2021
|
gptkbp:withdrawn
|
gptkb:United_States
May 2023
|
gptkbp:bfsParent
|
gptkb:COVID-19_vaccines_(for_Johnson_&_Johnson_and_AstraZeneca)
|
gptkbp:bfsLayer
|
6
|